Urogen Pharma

Urogen Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

Company Details

Employees
309
Founded
-
Address
400 Alexander Park Drive,
Phone
1(646)768-9780
Email
in****@****gen.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
urogen.com
HQ
Princeton, New Jersey
Looking for a particular Urogen Pharma employee's phone or email?

Urogen Pharma Questions

News

UroGen Pharma to Present at Upcoming Investor Conferences - Yahoo Finance

UroGen Pharma to Present at Upcoming Investor Conferences Yahoo Finance

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewswire

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 GlobeNewswire

67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth - Stock Titan

67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth Stock Titan

UroGen Pharma Announces Publication of Phase 3b Study on At-Home Administration of ZUSDURI™ for Bladder Cancer Treatment - Quiver Quantitative

UroGen Pharma Announces Publication of Phase 3b Study on At-Home Administration of ZUSDURI™ for Bladder Cancer Treatment Quiver Quantitative

UroGen Pharma Provides Business Update - citybiz

UroGen Pharma Provides Business Update citybiz

UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 - Stock Titan

UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 Stock Titan

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer - Yahoo Finance

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer Yahoo Finance

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Business Wire

Biotech Leader UroGen Pharma Announces Triple Conference Schedule: Wells Fargo, Cantor, H.C. Wainwright - Stock Titan

Biotech Leader UroGen Pharma Announces Triple Conference Schedule: Wells Fargo, Cantor, H.C. Wainwright Stock Titan

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Yahoo Finance

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer Yahoo Finance

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update Business Wire

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Business Wire

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - Yahoo Finance

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers Yahoo Finance

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Business Wire

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Business Wire

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations Business Wire

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA - FinancialContent

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA FinancialContent

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - FinancialContent

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 FinancialContent

NDA submitted to FDA for UGN-102 in low-grade intermediate-risk NMIBC - Urology Times

NDA submitted to FDA for UGN-102 in low-grade intermediate-risk NMIBC Urology Times

FDA accepts IND application for UGN-103 in NMIBC - Urology Times

FDA accepts IND application for UGN-103 in NMIBC Urology Times

FDA to host advisory committee meeting on UGN-102 for NMIBC - Urology Times

FDA to host advisory committee meeting on UGN-102 for NMIBC Urology Times

UGN-102 demonstrates long-term durability in NMIBC - Urology Times

UGN-102 demonstrates long-term durability in NMIBC Urology Times

UroGen Pharma to Present at Upcoming Investor Conferences - FinancialContent

UroGen Pharma to Present at Upcoming Investor Conferences FinancialContent

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - FinancialContent

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference FinancialContent

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors - FinancialContent

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors FinancialContent

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments - FinancialContent

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments FinancialContent

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 - FinancialContent

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 FinancialContent

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 | Silicon Investor (SI) -- The First Internet Community - FinancialContent

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 | Silicon Investor (SI) -- The First Internet Community FinancialContent

User - FinancialContent

User FinancialContent

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event - FinancialContent

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event FinancialContent

Top Urogen Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant